EUVIMEDEUVIMED entdecken
Übersichtsarbeit

MetALD : A narrative review of the clinical and molecular landscape of reclassifying steatotic liver disease

Butros Fakhoury, Ivonne Hurtado Díaz de León, Krishan S Patel, Luis Antonio Díaz, Juan Pablo Arab iD

Alcohol, Clinical and Experimental Research · 2026-02 · 50 (2)

DOI: 10.1111/acer.70259 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Alcohol, Clinical and Experimental Research, online erschienen am 24.02.2026. Verfasst von Butros Fakhoury und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Virginia Commonwealth University, Richmond, Virginia, USA. Hauptthemen laut MEDLINE: Fatty Liver, Alcoholic, Fatty Liver. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 108 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction and alcohol‐associated liver disease (MetALD) represents a distinct subgroup of steatotic liver disease (SLD), characterized by hepatic steatosis driven by concurrent metabolic dysfunction and heavy alcohol intake. Alcohol consumption remains a primary modifiable risk factor, potentiating liver disease progression, particularly when combined with metabolic comorbidities, such as obesity, insulin resistance, dyslipidemia, and hypertension. Genetic variants, including PNPLA3 , TM6SF2 , and MBOAT7 , further influence individual susceptibility, exacerbating hepatic injury and fibrosis. Pathophysiologically, MetALD arises from a complex interplay of intrahepatic and extrahepatic mechanisms, notably adipose tissue dysfunction, gut–liver axis dysbiosis, increased intestinal permeability, and disrupted bile acid signaling pathways. Hepatic lipotoxicity, cellular injury, immune activation, and subsequent fibrogenesis are central processes accelerating progression to advanced fibrosis, cirrhosis, and hepatocellular carcinoma. Diagnostic challenges persist, primarily due to inconsistent definitions of significant alcohol intake and metabolic dysfunction criteria, complicating disease classification. Liver biopsy, though definitive, frequently fails to discriminate MetALD from isolated metabolic or alcohol‐associated etiologies due to overlapping histological features. Management strategies for MetALD necessitate an integrated approach targeting both metabolic and alcohol‐related factors, emphasizing lifestyle interventions, alcohol cessation programs, and pharmacotherapy. Promising pharmacologic agents include medications for alcohol use disorder (e.g., naltrexone) and agents that may reduce liver fat and alcohol consumption concurrently, such as glucagon‐like peptide‐1 receptor agonists and FGF21 analogs. Despite growing recognition, MetALD remains under‐studied, highlighting critical research gaps, including refined diagnostic criteria, noninvasive biomarkers, tailored clinical trials, and comprehensive outcome assessments. Addressing these gaps is essential to improve prognostication, risk stratification, and therapeutic outcomes in this increasingly prevalent clinical entity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fatty Liver, AlcoholicFatty LiverHumansAnimalsPhospholipases A2, Calcium-IndependentLiverAcyltransferasesMembrane ProteinsAlcohol DrinkingLipase

Stichwörter der Autor:innen

alcoholic cirrhosiscirrhosisfatty livernonalcoholic fatty liver disease

Substanzen

Phospholipases A2, Calcium-IndependentAcyltransferasesMembrane ProteinsLipase

Autor:innen und Institutionen

  • Department of Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
  • Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
  • MASLD Research Center, Division of Gastroenterology and Hepatology, University of California San Diego, California, USA.
  • Departamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
  • Division of Gastroenterology, Hepatology, and Nutrition, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.

ORCID-Profile: Juan Pablo Arab

Zitieren

APA

Fakhoury, B., Hurtado Díaz de León, I., Patel, K. S., Díaz, L. A., & Arab, J. P. (2026). MetALD : A narrative review of the clinical and molecular landscape of reclassifying steatotic liver disease. Alcohol, Clinical and Experimental Research, 50(2). https://doi.org/10.1111/acer.70259

Vancouver

Fakhoury B, Hurtado Díaz de León I, Patel KS, Díaz LA, Arab JP. MetALD : A narrative review of the clinical and molecular landscape of reclassifying steatotic liver disease. Alcohol, Clinical and Experimental Research. 2026;50(2). doi:10.1111/acer.70259

BibTeX
@article{Fakhoury2026,
  author = {Fakhoury, Butros and Hurtado Díaz de León, Ivonne and Patel, Krishan S and Díaz, Luis Antonio and Arab, Juan Pablo},
  title = {MetALD : A narrative review of the clinical and molecular landscape of reclassifying steatotic liver disease},
  journal = {Alcohol, Clinical and Experimental Research},
  year = {2026},
  volume = {50},
  number = {2},
  doi = {10.1111/acer.70259}
}
Kostenlos starten →